Genedrive Dividenda 2024

Detalji o dividendama

Razumevanje dividendnih isplata od Genedrive

Dividende od Genedrive su deo profita kompanije koji se distribuira akcionarima. One su ključni indikator finansijskog zdravlja kompanije i atraktivnosti za investitore. Dividende pružaju investitorima stabilan izvor prihoda, pored dobiti koja se možda može ostvariti prodajom akcija po višoj ceni od kupovne.

Poređenje iz godine u godinu

Analiza isplata dividendi od Genedrive tokom godina može istaći profitabilnost i stabilnost kompanije. Konstantno ili rastuće isplate dividendi mogu ukazivati na finansijski zdravu kompaniju sa predvidivim profitom, dok fluktuacije ili smanjenja dividendi mogu signalizirati osnovne finansijske ili operativne izazove.

Uticaj na investicije

Isplate dividendi od Genedrive su suštinski faktor za investitore orijentisane na prihod. Robusna isplata dividendi može povećati privlačnost akcije i pružiti redovni prihod pored potencijalnih kapitalnih dobitaka. Ona može takođe pokazati poverenje kompanije u njene buduće profite i time biti značajan faktor za odlučivanje o investicijama.

Interpretacija fluktuacija dividendi

Promene u dividendama od Genedrive mogu proistići iz promena u profitima kompanije, finansijskoj politici ili strategijama reinvestiranja. Povećanje dividendi često signalizira finansijsku stabilnost, dok smanjenje može ukazivati na potrebu da se sačuva gotovina ili da se profiti reinvestiraju radi podsticanja rasta, pri čemu svaki scenario ima različite posledice za investitore.

Genedrive Aktienanalyse

Шта ради Genedrive?

Genedrive PLC is a biomedical company based in Manchester, United Kingdom, specializing in the development of innovative diagnostic tests for infectious diseases and cancer. The company was founded in 2007 under the name Epistem Limited and went public in 2013. The business model of Genedrive involves developing and distributing innovative molecular diagnostic tests for diseases worldwide. The company's main goal is to change the way infectious diseases and cancer are diagnosed and treated by offering rapid, accurate, and cost-effective tests. The company has two main divisions: Genprobe and Instruments. Under Genprobe, various in vitro diagnostic tests for infectious diseases and diseases of the human immune system, including tuberculosis, hepatitis C, hepatitis B, HIV, and others, are offered. Under Instruments, Genedrive offers PCR instruments used for analyzing samples for DNA and RNA sequences. Some of Genedrive's key products include: - Genedrive HCV-ID Testkit: A test kit for identifying and quantifying hepatitis C viruses (HCV) in human blood samples. The test provides results within 90 minutes and has high accuracy. - Genedrive MT-RNR1 Testkit: A test kit for the rapid diagnosis of tuberculosis (TB), one of the most common infectious diseases worldwide. The test utilizes PCR technology and provides results within 90 minutes. - Genedrive Genedrive 96: An instrument for simultaneous analysis of up to 96 PCR samples. The system offers high accuracy and precision in analyzing RNA and DNA sequences. The company collaborates closely with leading research institutions and health organizations worldwide to improve its products and develop new tests. Genedrive has formed partnerships with the British government, the US Department of Defense, and other institutions. In recent years, the company has made significant progress in developing new diagnostic tests for infectious diseases and cancer. For example, Genedrive recently signed an agreement with the Foundation for Innovative New Diagnostics (FIND) to develop a molecular test for the Ebola virus. The company also has a pipeline of projects, including tests for COVID-19 and antibiotic resistance. Despite Genedrive's success, the company remains committed to innovation and research in order to transform the diagnostics industry and improve the health of people worldwide. Genedrive is expected to continue playing an important role in the fight against infectious diseases and cancer in the future. Genedrive je jedna od najpopularnijih kompanija na Eulerpool.com.

Često postavljana pitanja o Genedrive akciji

Kolika je dividenda koju isplaćuje Genedrive?

U poslednjih 12 meseci, Genedrive je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Genedrive će verovatno isplatiti dividendu od 0 GBP.

Kolika je dividendna prinosa za Genedrive?

Dividendski prinos od Genedrive trenutno iznosi .

Kada Genedrive isplaćuje dividendu?

Genedrive isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Genedrive?

Genedrive je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Genedrive?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 GBP. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Genedrive?

Genedrive se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Genedrive kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Genedrive od 27. 10. 2024. u iznosu od 0 GBP, morali ste da imate akciju u depou pre Ex-dana 27. 10. 2024..

Kada je Genedrive poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 27. 10. 2024..

Kolika je bila dividenda od Genedrive u godini 2023?

U godini 2023 kompanija Genedrive je isplatila 0 GBP kao dividende.

U kojoj valuti Genedrive isplaćuje dividendu?

Dividende od Genedrive se isplaćuju u GBP.